The Food and Drug Administration approved on Friday a label change for Pfizer's birth control shot Depo-Provera that warns ...
The FDA contacted J&J right after ASH to discuss using a special fast pass on a multiple myeloma regimen. Elsewhere, a new ...
Representatives of companies including AbbVie, Eli Lilly, Johnson & Johnson and Merck have voiced concerns about the FDA’s ...
There is plenty to be wary of with this drugmaker, but there are also reasons to be optimistic.
Morgan Stanley ($MS) has issued a less optimistic outlook on the performance of the shares of American pharmaceutical giant ...
Shares of BioNTech, the German vaccine innovator, came under significant pressure on a pivotal Tuesday. The sell-off, which also dragged down sector peers in ...
Keep your expectations in check.
Pfizer's stock has fallen by more than 50% from its 2021 highs and faces some headwinds, but remains worth a deep dive for long-term investors.
Pfizer bets on YaoPharma’s oral GLP-1 pill YP05002 after past failures, aiming to rejoin the booming $150B obesity-drug market.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback